Ionis Pharmaceuticals Inc (IONS) Plunges After GSK Foregos Phase 3 Study of TTRRx
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares have plunged by 35% this morning after GlaxoSmithKline (NYSE:GSK), which has an option to exclusively license IONIS-TTRRx, decided not to initiate a Phase...